Literature DB >> 24861909

Albiglutide: first global approval.

Raewyn M Poole1, Mary L Nowlan.   

Abstract

Albiglutide (Eperzan® [EU]; Tanzeum™ [US]), a glucagon-like peptide 1 receptor agonist, has been developed by GlaxoSmithKline for the treatment of type 2 diabetes mellitus (T2DM). Albiglutide has received its first global approval in this indication in the EU, for use in combination with other antihyperglycaemic agents, including basal insulin, when these drugs and diet and exercise do not provide adequate glycaemic control, and as monotherapy in patients unable to take metformin due to contraindications or intolerance when diet and exercise alone do not provide adequate glycaemic control. Albiglutide has subsequently been approved for the second-line or later treatment of T2DM as an adjunct to diet and exercise in the US. This article summarizes the milestones in the development of albiglutide leading to this first approval for the treatment of T2DM.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24861909     DOI： 10.1007/s40265-014-0228-2

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  10 in total

1.  Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.

Authors:  Yutaka Seino; Hiromu Nakajima; Hajime Miyahara; Takashi Kurita; Mark A Bush; Fred Yang; Murray W Stewart
Journal:  Curr Med Res Opin       Date:  2009-12       Impact factor: 2.580

Review 2.  Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.

Authors:  Martin Lorenz; Andreas Evers; Michael Wagner
Journal:  Bioorg Med Chem Lett       Date:  2013-05-16       Impact factor: 2.823

3.  Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.

Authors:  Mark Bush; Rhona Scott; Prapoch Watanalumlerd; Hui Zhi; Eric Lewis
Journal:  Postgrad Med       Date:  2012-11       Impact factor: 3.840

4.  A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

Authors:  Laurie L Baggio; Qingling Huang; Theodore J Brown; Daniel J Drucker
Journal:  Diabetes       Date:  2004-09       Impact factor: 9.461

5.  Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.

Authors:  M A Bush; J E Matthews; E H De Boever; R L Dobbins; R J Hodge; S E Walker; M C Holland; M Gutierrez; M W Stewart
Journal:  Diabetes Obes Metab       Date:  2008-02-11       Impact factor: 6.577

Review 6.  Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2010-05       Impact factor: 9.461

7.  Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.

Authors:  Julio Rosenstock; Jane Reusch; Mark Bush; Fred Yang; Murray Stewart
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 19.112

8.  Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

Authors:  Richard E Pratley; Michael A Nauck; Anthony H Barnett; Mark N Feinglos; Fernando Ovalle; Illana Harman-Boehm; June Ye; Rhona Scott; Susan Johnson; Murray Stewart; Julio Rosenstock
Journal:  Lancet Diabetes Endocrinol       Date:  2014-02-06       Impact factor: 32.069

9.  Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review.

Authors:  Helen Berlie; Kathryn M Hurren; Nicole R Pinelli
Journal:  Diabetes Metab Syndr Obes       Date:  2012-07-03       Impact factor: 3.168

10.  Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency.

Authors:  Weike Bao; Karpagam Aravindhan; Hasan Alsaid; Thimmaiah Chendrimada; Matthew Szapacs; David R Citerone; Mark R Harpel; Robert N Willette; John J Lepore; Beat M Jucker
Journal:  PLoS One       Date:  2011-08-26       Impact factor: 3.240
  10 in total
  6 in total

Review 1.  Strategic approaches to optimizing peptide ADME properties.

Authors:  Li Di
Journal:  AAPS J       Date:  2014-11-04       Impact factor: 4.009

Review 2.  Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 3.  Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics.

Authors:  Kine Marita Knudsen Sand; Malin Bern; Jeannette Nilsen; Hanna Theodora Noordzij; Inger Sandlie; Jan Terje Andersen
Journal:  Front Immunol       Date:  2015-01-26       Impact factor: 7.561

Review 4.  Albumin-based drug delivery: harnessing nature to cure disease.

Authors:  Maja Thim Larsen; Matthias Kuhlmann; Michael Lykke Hvam; Kenneth A Howard
Journal:  Mol Cell Ther       Date:  2016-02-27

Review 5.  The Neonatal Fc Receptor (FcRn): A Misnomer?

Authors:  Michal Pyzik; Kine M K Sand; Jonathan J Hubbard; Jan Terje Andersen; Inger Sandlie; Richard S Blumberg
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

Review 6.  Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future.

Authors:  Sanjay Kalra; Manash P Baruah; Rakesh K Sahay; Ambika Gopalakrishnan Unnikrishnan; Shweta Uppal; Omolara Adetunji
Journal:  Indian J Endocrinol Metab       Date:  2016 Mar-Apr
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.